Hikma Pharmaceuticals PLC on Tuesday said it launched an authorised generic version of the Xyrem sodium oxybate prescription medicine in the US for treating narcolepsy.
The London-based pharmaceutical company said its version is based on Jazz Pharmaceuticals’ Xyrem oral solution CIII and will be used to treat symptoms of excessive daytime sleepiness and sudden onset of weak or paralysed muscles, otherwise known as cataplexy.
Hikma will have 180 days of marketing exclusivity for its authorised generic product in the US.
It cited Jazz Pharmaceuticals reported net sales for Xyrem of around $1.3 billion in 2021.
‘We are pleased to be able to provide the first authorised generic version of Xyrem to patients and health care providers in the US. This launch further expands our diversified portfolio of generic products, and underscores our ability to put ’Better Health, Within Reach, Every Day’ for the millions of people who rely on our medicines,’ said Brian Hoffmann, Hikma’s president of generics.
Shares in Hikma were up 5.6% to 1,639.00 pence each in London on Tuesday morning.
Copyright 2023 Alliance News Ltd. All Rights Reserved.
